|
1
|
Santos ED, Hernández MH, Sérazin V, Vialard F, Dieudonné MN. Human Placental Adaptive Changes in Response to Maternal Obesity: Sex Specificities. Int J Mol Sci 2023; 24:ijms24119770. [PMID: 37298720 DOI: 10.3390/ijms24119770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2023] [Revised: 05/25/2023] [Accepted: 05/31/2023] [Indexed: 06/12/2023] Open
Abstract
Maternal obesity is increasingly prevalent and is associated with elevated morbidity and mortality rates in both mothers and children. At the interface between the mother and the fetus, the placenta mediates the impact of the maternal environment on fetal development. Most of the literature presents data on the effects of maternal obesity on placental functions and does not exclude potentially confounding factors such as metabolic diseases (e.g., gestational diabetes). In this context, the focus of this review mainly lies on the impact of maternal obesity (in the absence of gestational diabetes) on (i) endocrine function, (ii) morphological characteristics, (iii) nutrient exchanges and metabolism, (iv) inflammatory/immune status, (v) oxidative stress, and (vi) transcriptome. Moreover, some of those placental changes in response to maternal obesity could be supported by fetal sex. A better understanding of sex-specific placental responses to maternal obesity seems to be crucial for improving pregnancy outcomes and the health of mothers and children.
Collapse
Affiliation(s)
- Esther Dos Santos
- UFR des Sciences de la Santé Simone Veil, Université de Versailles-Saint Quentin en Yvelines-Université Paris Saclay (UVSQ), INRAE, BREED, F-78350 Jouy-en-Josas, France
- Ecole Nationale Vétérinaire d'Alfort (EnvA), BREED, F-94700 Maisons-Alfort, France
- Service de Biologie Médicale, Centre Hospitalier de Poissy-Saint Germain, F-78300 Poissy, France
| | - Marta Hita Hernández
- UFR des Sciences de la Santé Simone Veil, Université de Versailles-Saint Quentin en Yvelines-Université Paris Saclay (UVSQ), INRAE, BREED, F-78350 Jouy-en-Josas, France
- Ecole Nationale Vétérinaire d'Alfort (EnvA), BREED, F-94700 Maisons-Alfort, France
| | - Valérie Sérazin
- UFR des Sciences de la Santé Simone Veil, Université de Versailles-Saint Quentin en Yvelines-Université Paris Saclay (UVSQ), INRAE, BREED, F-78350 Jouy-en-Josas, France
- Ecole Nationale Vétérinaire d'Alfort (EnvA), BREED, F-94700 Maisons-Alfort, France
- Service de Biologie Médicale, Centre Hospitalier de Poissy-Saint Germain, F-78300 Poissy, France
| | - François Vialard
- UFR des Sciences de la Santé Simone Veil, Université de Versailles-Saint Quentin en Yvelines-Université Paris Saclay (UVSQ), INRAE, BREED, F-78350 Jouy-en-Josas, France
- Ecole Nationale Vétérinaire d'Alfort (EnvA), BREED, F-94700 Maisons-Alfort, France
- Service de Biologie Médicale, Centre Hospitalier de Poissy-Saint Germain, F-78300 Poissy, France
| | - Marie-Noëlle Dieudonné
- UFR des Sciences de la Santé Simone Veil, Université de Versailles-Saint Quentin en Yvelines-Université Paris Saclay (UVSQ), INRAE, BREED, F-78350 Jouy-en-Josas, France
- Ecole Nationale Vétérinaire d'Alfort (EnvA), BREED, F-94700 Maisons-Alfort, France
| |
Collapse
|
|
2
|
Hernández MH, Dos Santos E, Rodriguez Y, Priou C, Berveiller P, Vialard F, Dieudonné MN. Influence of maternal obesity on human trophoblast differentiation: The role of mitochondrial status. Reprod Biol 2022; 22:100650. [DOI: 10.1016/j.repbio.2022.100650] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2022] [Revised: 04/26/2022] [Accepted: 05/03/2022] [Indexed: 10/18/2022]
|
|
3
|
Fraichard C, Bonnet-Serrano F, Laguillier-Morizot C, Hebert-Schuster M, Lai-Kuen R, Sibiude J, Fournier T, Cohen M, Guibourdenche J. Protease Inhibitor Anti-HIV, Lopinavir, Impairs Placental Endocrine Function. Int J Mol Sci 2021; 22:E683. [PMID: 33445576 PMCID: PMC7827556 DOI: 10.3390/ijms22020683] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2020] [Revised: 01/06/2021] [Accepted: 01/08/2021] [Indexed: 12/12/2022] Open
Abstract
Protease Inhibitors (PI e.g., ritonavir (RTV) and lopinavir (LPV)) used to treat pregnant mothers infected by HIV induce prematurity and endocrine dysfunctions. The maintenance of pregnancy relies on placental hormone production (human Chorionic Gonadotrophin (hCG) and progesterone (P4)). Those functions are ensured by the villous trophoblast and are mainly regulated by the Unfolded Protein Response (UPR) pathway and mitochondria. We investigated, in vitro, if PI impair hCG and P4 production and the potential intracellular mechanisms involved. Term villous cytotrophoblast (VCT) were cultured with or without RTV or LPV from 6 to 48 h. VCT differentiation into syncytiotrophoblast (ST) was followed measuring hCG and P4 secretion. We evaluated the expression of P4 synthesis partners (Metastatic Lymph Node 64 (MLN64), cholesterol side-chain cleavage (P450SCC), Hydroxy-delta-5-Steroid Dehydrogenase and 3 Beta-and steroid delta-isomerase 1 (HSD3B1)), of mitochondrial pro-fusion factors (Mitofusin 2 (Mfn2), Optic Atrophy 1 (OPA1)) and of UPR factors (Glucose-Regulated Protein 78 (GRP78), Activating Transcription Factor 4 (ATF4), Activating Transcription Factor 6 (ATF6), spliced X-box Binding Protein 1 (sXBP1)). RTV had no significant effect on hCG and P4 secretion, whereas lopinavir significantly decreased both secretions. LPV also decreased P450SCC and HSD3B1 expression, whereas it increased Mfn2, GRP78 and sXBP1 expression in ST. RTV has no effect on the endocrine placenta. LPV impairs both villous trophoblast differentiation and P4 production. It is likely to act via mitochondrial fusion and UPR pathway activation. These trophoblastic alterations may end in decreased P4 levels in maternal circulation, inducing prematurity.
Collapse
Affiliation(s)
- Camille Fraichard
- INSERM UMR-S 1139, Faculté de Pharmacie, Université de Paris, 75006 Paris, France; (C.F.); (C.L.-M.); (T.F.)
| | | | - Christelle Laguillier-Morizot
- INSERM UMR-S 1139, Faculté de Pharmacie, Université de Paris, 75006 Paris, France; (C.F.); (C.L.-M.); (T.F.)
- Service d’Hormonologie, CHU Cochin, HUPC, AP-HP, 75014 Paris, France;
| | - Marylise Hebert-Schuster
- Service de Gynécologie-Obstétrique, Faculté de Médecine, Université de Genève, 1206 Genève, Suisse; (M.H.-S.); (M.C.)
| | - René Lai-Kuen
- INSERM UMS 025—CNRS UMS 3612, Faculté de Pharmacie, Université de Paris, 75006 Paris, France;
| | - Jeanne Sibiude
- Service de Gynécologie-Obstétrique, CHU Louis Mourier, HUPN, AP-HP, 92700 Colombes, France;
| | - Thierry Fournier
- INSERM UMR-S 1139, Faculté de Pharmacie, Université de Paris, 75006 Paris, France; (C.F.); (C.L.-M.); (T.F.)
| | - Marie Cohen
- Service de Gynécologie-Obstétrique, Faculté de Médecine, Université de Genève, 1206 Genève, Suisse; (M.H.-S.); (M.C.)
| | - Jean Guibourdenche
- INSERM UMR-S 1139, Faculté de Pharmacie, Université de Paris, 75006 Paris, France; (C.F.); (C.L.-M.); (T.F.)
- Service d’Hormonologie, CHU Cochin, HUPC, AP-HP, 75014 Paris, France;
| |
Collapse
|
|
4
|
Nedder M, Boland S, Devineau S, Zerrad-Saadi A, Rogozarski J, Lai-Kuen R, Baya I, Guibourdenche J, Vibert F, Chissey A, Gil S, Coumoul X, Fournier T, Ferecatu I. Uptake of Cerium Dioxide Nanoparticles and Impact on Viability, Differentiation and Functions of Primary Trophoblast Cells from Human Placenta. NANOMATERIALS 2020; 10:nano10071309. [PMID: 32635405 PMCID: PMC7407216 DOI: 10.3390/nano10071309] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/18/2020] [Revised: 06/30/2020] [Accepted: 07/02/2020] [Indexed: 02/07/2023]
Abstract
The human placenta is at the interface between maternal and fetal circulations, and is crucial for fetal development. The nanoparticles of cerium dioxide (CeO2 NPs) from air pollution are an unevaluated risk during pregnancy. Assessing the consequences of placenta exposure to CeO2 NPs could contribute to a better understanding of NPs’ effect on the development and functions of the placenta and pregnancy outcome. We used primary villous cytotrophoblasts purified from term human placenta, with a wide range of CeO2 NPs concentrations (0.1–101 μg/cm2) and exposure time (24–72 h), to assess trophoblast uptake, toxicity and impact on trophoblast differentiation and endocrine function. We have shown the capacity of both cytotrophoblasts and syncytiotrophoblasts to internalize CeO2 NPs. CeO2 NPs affected trophoblast metabolic activity in a dose and time dependency, induced caspase activation and a LDH release in the absence of oxidative stress. CeO2 NPs decreased the fusion capacity of cytotrophoblasts to form a syncytiotrophoblast and disturbed secretion of the pregnancy hormones hCG, hPL, PlGF, P4 and E2, in accordance with NPs concentration. This is the first study on the impact of CeO2 NPs using human primary trophoblasts that decrypts their toxicity and impact on placental formation and functions.
Collapse
Affiliation(s)
- Margaux Nedder
- Faculté de Pharmacie de Paris, Université de Paris, INSERM UMR-S 1139, 3PHM, F-75006 Paris, France; (M.N.); (A.Z.-S.); (J.R.); (I.B.); (J.G.); (F.V.); (A.C.); (S.G.); (T.F.)
| | - Sonja Boland
- BFA, Université de Paris, UMR 8251, CNRS, F-75013 Paris, France; (S.B.); (S.D.)
| | - Stéphanie Devineau
- BFA, Université de Paris, UMR 8251, CNRS, F-75013 Paris, France; (S.B.); (S.D.)
| | - Amal Zerrad-Saadi
- Faculté de Pharmacie de Paris, Université de Paris, INSERM UMR-S 1139, 3PHM, F-75006 Paris, France; (M.N.); (A.Z.-S.); (J.R.); (I.B.); (J.G.); (F.V.); (A.C.); (S.G.); (T.F.)
| | - Jasmina Rogozarski
- Faculté de Pharmacie de Paris, Université de Paris, INSERM UMR-S 1139, 3PHM, F-75006 Paris, France; (M.N.); (A.Z.-S.); (J.R.); (I.B.); (J.G.); (F.V.); (A.C.); (S.G.); (T.F.)
| | - René Lai-Kuen
- Faculté de Pharmacie de Paris, Université de Paris, INSERM UMS 025—CNRS UMS 3612, F-75006 Paris, France;
| | - Ibtissem Baya
- Faculté de Pharmacie de Paris, Université de Paris, INSERM UMR-S 1139, 3PHM, F-75006 Paris, France; (M.N.); (A.Z.-S.); (J.R.); (I.B.); (J.G.); (F.V.); (A.C.); (S.G.); (T.F.)
| | - Jean Guibourdenche
- Faculté de Pharmacie de Paris, Université de Paris, INSERM UMR-S 1139, 3PHM, F-75006 Paris, France; (M.N.); (A.Z.-S.); (J.R.); (I.B.); (J.G.); (F.V.); (A.C.); (S.G.); (T.F.)
- Assistance Publique—Hôpitaux de Paris, Hôpital Cochin, Service d’hormonologie, F-75014 Paris, France
| | - Francoise Vibert
- Faculté de Pharmacie de Paris, Université de Paris, INSERM UMR-S 1139, 3PHM, F-75006 Paris, France; (M.N.); (A.Z.-S.); (J.R.); (I.B.); (J.G.); (F.V.); (A.C.); (S.G.); (T.F.)
| | - Audrey Chissey
- Faculté de Pharmacie de Paris, Université de Paris, INSERM UMR-S 1139, 3PHM, F-75006 Paris, France; (M.N.); (A.Z.-S.); (J.R.); (I.B.); (J.G.); (F.V.); (A.C.); (S.G.); (T.F.)
| | - Sophie Gil
- Faculté de Pharmacie de Paris, Université de Paris, INSERM UMR-S 1139, 3PHM, F-75006 Paris, France; (M.N.); (A.Z.-S.); (J.R.); (I.B.); (J.G.); (F.V.); (A.C.); (S.G.); (T.F.)
| | - Xavier Coumoul
- Université de Paris, INSERM UMR-S 1124, F-75006 Paris, France;
| | - Thierry Fournier
- Faculté de Pharmacie de Paris, Université de Paris, INSERM UMR-S 1139, 3PHM, F-75006 Paris, France; (M.N.); (A.Z.-S.); (J.R.); (I.B.); (J.G.); (F.V.); (A.C.); (S.G.); (T.F.)
| | - Ioana Ferecatu
- Faculté de Pharmacie de Paris, Université de Paris, INSERM UMR-S 1139, 3PHM, F-75006 Paris, France; (M.N.); (A.Z.-S.); (J.R.); (I.B.); (J.G.); (F.V.); (A.C.); (S.G.); (T.F.)
- Correspondence: ; Tel.: +33-1-53-73-96-05; Fax: +33-1-44-07-39-92
| |
Collapse
|